Literature DB >> 16630118

Expression patterns of polo-like kinase 1 in human gastric cancer.

Wilko Weichert1, Andrea Ullrich, Mathias Schmidt, Volker Gekeler, Aurelia Noske, Silvia Niesporek, Ann-Christin Buckendahl, Manfred Dietel, Carsten Denkert.   

Abstract

Polo-like kinase 1 (PLK1) is centrally involved in the regulation of mitosis in normal and malignant cells. It is known that inhibition of PLK1 expression in vitro and in vivo leads to mitotic arrest, induction of apoptosis and suppression of tumor growth. In the present study, expression of PLK1 was investigated in paraffin tissue of 135 cases of gastric adenocarcinoma and in 46 corresponding lymph node metastases by immunohistochemistry. Expression data were correlated with clinicopathological parameters and patient survival. Seventy-three (54.1%) of 135 carcinomas showed an overexpression of PLK1 compared to normal gastric mucosa. Overexpression of PLK1 correlated positively with tumor stage, nodal status and diffuse growth pattern. PLK1 expression in the primary tumor did not differ from PLK1 expression in the corresponding lymph node metastases. PLK1 expression was a significant prognostic factor in univariate but not in multivariate survival analysis. As a conclusion, upregulated PLK1 expression in gastric cancer correlates with a malignant tumor phenotype and has impact on patient prognosis. These data underscore the importance of PLK1 in gastric carcinogenesis and present a translational link for functional data into potential clinical use by defining PLK1 as an attractive protein for novel targeted chemotherapeutic approaches in gastric cancer. (Cancer Sci 2006; 97: 271 -276).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16630118     DOI: 10.1111/j.1349-7006.2006.00170.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  26 in total

Review 1.  Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.

Authors:  Klaus Strebhardt
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

Review 2.  Satellite Cells in Muscular Dystrophy - Lost in Polarity.

Authors:  Natasha C Chang; Fabien P Chevalier; Michael A Rudnicki
Journal:  Trends Mol Med       Date:  2016-05-05       Impact factor: 11.951

Review 3.  Current progress of siRNA/shRNA therapeutics in clinical trials.

Authors:  John C Burnett; John J Rossi; Katrin Tiemann
Journal:  Biotechnol J       Date:  2011-07-11       Impact factor: 4.677

4.  Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.

Authors:  Richard Gorlick; E Anders Kolb; Stephen T Keir; John M Maris; C Patrick Reynolds; Min H Kang; Hernan Carol; Richard Lock; Catherine A Billups; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2013-08-19       Impact factor: 3.167

5.  Identification of inhibitors of the polo-box domain of polo-like kinase 1 from natural and semisynthetic compounds.

Authors:  Sara Abdelfatah; Edmond Fleischer; Anette Klinger; Vincent Kam Wai Wong; Thomas Efferth
Journal:  Invest New Drugs       Date:  2019-03-15       Impact factor: 3.850

Review 6.  Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy.

Authors:  Yingmei Wang; Ping Ji; Jinsong Liu; Russell R Broaddus; Fengxia Xue; Wei Zhang
Journal:  Mol Cancer       Date:  2009-02-13       Impact factor: 27.401

Review 7.  Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications.

Authors:  Ion Cristóbal; Federico Rojo; Juan Madoz-Gúrpide; Jesús García-Foncillas
Journal:  Mol Cell Biol       Date:  2016-05-31       Impact factor: 4.272

Review 8.  Gastric cancer in the era of molecularly targeted agents: current drug development strategies.

Authors:  Hendrik-Tobias Arkenau
Journal:  J Cancer Res Clin Oncol       Date:  2009-04-11       Impact factor: 4.553

9.  Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients.

Authors:  Zi-Li He; He Zheng; Hui Lin; Xiong-Ying Miao; De-Wu Zhong
Journal:  World J Gastroenterol       Date:  2009-09-07       Impact factor: 5.742

Review 10.  Modulating polo-like kinase 1 as a means for cancer chemoprevention.

Authors:  Travis L Schmit; Mark C Ledesma; Nihal Ahmad
Journal:  Pharm Res       Date:  2010-01-27       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.